METABOSET

Unraveling metabolic settings and targeting metabolic enzymes with selective lethality in BRAF and NRAS mutant melanoma tumors

Coordinatore	FUNDACIO INSTITUT DE RECERCA DE L'HOSPITAL UNIVERSITARI VALL D'HEBRON    more  Organization address address: Passeig Vall d'Hebron city: BARCELONA postcode: 8035 contact info Titolo: Ms. Nome: Raquel Cognome: Fornell Email: send email Telefono: 34934894947 Fax: 34932746708
Nazionalità Coordinatore	Spain [ES]
Totale costo	173˙370 €
EC contributo	173˙370 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2013-IEF
Funding Scheme	MC-IEF
Anno di inizio	2014
Periodo (anno-mese-giorno)	2014-04-01   -   2016-03-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	FUNDACIO INSTITUT DE RECERCA DE L'HOSPITAL UNIVERSITARI VALL D'HEBRON  Organization address address: Passeig Vall d'Hebron city: BARCELONA postcode: 8035 contact info Titolo: Ms. Nome: Raquel Cognome: Fornell Email: send email Telefono: 34934894947 Fax: 34932746708	ES (BARCELONA)	coordinator	173˙370.60

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Melanoma is the most lethal form of skin cancer. Therapeutic alternatives to metastatic melanoma are very limited. Activation of RAS pathway appears to be the central motor driving melanoma development and maintenance, where BRAFV600E and NRASQ61L are found in ~ 50% and 20% of human melanomas, respectively. Although, these mutually exclusive mutations affect the same pathway emerging preclinical and clinical evidence suggests that NRASQ61L mutant melanomas have patterns of signal transduction and biological behavior that is distinct from BRAFV600E mutant melanomas. These patterns include a differential response to metabolic stress. We believe that successful exploitation of mutations in melanoma will be dependent on understanding not only mutations and their frequency but their genetic and biochemical/metabolic context as well. The overall objective of the present project is to find novel therapeutic alternatives to treat NRASQ61L and/or BRAFV600E mutant melanoma tumours by targeting specific metabolic enzymes, such as Aldehyde Deshydrogenases, with potential synthetic lethality.'